Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 22:8:113.
doi: 10.3389/fnins.2014.00113. eCollection 2014.

Advances in non-dopaminergic treatments for Parkinson's disease

Affiliations
Review

Advances in non-dopaminergic treatments for Parkinson's disease

Sandy Stayte et al. Front Neurosci. .

Abstract

Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has resulted in extensive efforts to develop new therapies that work in ways other than restoring or replacing dopamine. Here we describe newly emerging non-dopaminergic therapeutic strategies for PD, including drugs targeting adenosine, glutamate, adrenergic, and serotonin receptors, as well as GLP-1 agonists, calcium channel blockers, iron chelators, anti-inflammatories, neurotrophic factors, and gene therapies. We provide a detailed account of their success in animal models and their translation to human clinical trials. We then consider how advances in understanding the mechanisms of PD, genetics, the possibility that PD may consist of multiple disease states, understanding of the etiology of PD in non-dopaminergic regions as well as advances in clinical trial design will be essential for ongoing advances. We conclude that despite the challenges ahead, patients have much cause for optimism that novel therapeutics that offer better disease management and/or which slow disease progression are inevitable.

Keywords: L-Dopa; Parkinson's disease; animal models; dopamine; dyskinesias; gene therapy; neurodegeneration; therapeutics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Basal ganglia dysfunction in PD. Diagram representing the normal function of the basal ganglia (left), the changes occurring in PD (right), and the site of primary action of therapeutic targets discussed in this review (numbered). Arrows represent the major neurotransmitters of glutamate (green), GABA (blue) and dopamine (red). Relative thickness of the arrows indicates level of activity of neurotransmitter. SNpc, substantia nigra pars compacta; SNr, substantia nigra reticulata; STN, subthalamic nucleus; MGP, medial globus pallidus; LGP, lateral globus pallidus.

References

    1. Aarsland D., Larsen J. P., Lim N. G., Janvin C., Karlsen K., Tandberg E., et al. (1999). Range of neuropsychiatric disturbances in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67, 492–496 10.1136/jnnp.67.4.492 - DOI - PMC - PubMed
    1. Abdipranoto-Cowley A., Park J. S., Croucher D., Daniel J., Henshall S., Galbraith S., et al. (2009). Activin A is essential for neurogenesis following neurodegeneration. Stem Cells 27, 1330–1346 10.1002/stem.80 - DOI - PMC - PubMed
    1. Albin R. L., Young A. B., Penney J. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366–375 10.1016/0166-2236(89)90074-X - DOI - PubMed
    1. Albin R. L., Young A. B., Penney J. B. (1995). The functional anatomy of disorders of the basal ganglia. Trends Neurosci. 18, 63–64 10.1016/0166-2236(95)80020-3 - DOI - PubMed
    1. Aldenkamp A. P., Baker G., Mulder O. G., Chadwick D., Cooper P., Doelman J., et al. (2000). A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41, 1167–1178 10.1111/j.1528-1157.2000.tb00322.x - DOI - PubMed

LinkOut - more resources